[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"plasmacytoid-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:plasmacytoid-lymphoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100374967","phase-1-bcma-cd19-ccar-in-multiple-myeloma-and-plasmacytoid-lymphoma-100374967",false,"NCT04162353","BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma","BCMA-CD19 cCAR in Relapsed and \u002For Refractory Multiple Myeloma and Plasmacytoid Lymphoma","Inclusion Criteria:\n\n* Signed written informed consent; Patients volunteer to participate in the research\n* Diagnosis is mainly based on the World Health Organization (WHO) 2008\n* Patients have exhausted standard therapeutic options\n* Systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 1 weeks\n* Female must be not pregnant during the study\n\nExclusion Criteria:\n\n* Patients declining to consent for treatment\n* Prior solid organ transplantation\n* Potentially curative therapy including chemotherapy or hematopoietic cell transplant\n* Prior treatment with BCMAxCD3 or CD19xCD3 bispecific agents","ALL",{"count":18,"type":19},12,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and\u002For refractory multiple myeloma and plasmacytoid lymphoma.",[25,26,27],"Multiple Myeloma in Relapse","Refractory Multiple Myeloma","Plasmacytoid; Lymphoma",[29,30,31,32,33],"BCMA","CD19","BCMA-CD19 cCAR T cells","multiple myeloma","plasmacytoid lymphoma","RECRUITING","2025-09-10",{"date":37,"type":38},"2025-09-16","ACTUAL",{"date":40,"type":38},"2019-07-01",{"date":42,"type":19},"2026-07",{"name":44,"class":45},"iCell Gene Therapeutics","INDUSTRY",2]